liver

A liver enzyme affects fibrosis progression by altering metabolism of the sugar trehalose in the gut.

As an alternative to daily pills, a new RNAi drug could lower blood pressure with a twice-yearly injection.

With a high mortality rate and no treatment, alcoholic hepatitis is a tragic diagnosis. But a new molecule that alters patient epigenetics may become the first effective therapy for the disease.

Scientists found that the Kisspeptin hormone activates enzymes that stop lipid formation in the mouse liver, suggesting that it has potential as a drug target for treating non-alcoholic fatty liver disease.

Through academic, industry, and governmental partnerships, scientists validate and develop non-invasive diagnostics for non-alcoholic fatty liver disease. These tests are set to replace the invasive and risky gold standard: liver biopsy.